HealthLynked Corp. HLYK

FY2025 · ended Dec 31, 2025 · Revenue $2.07M, -31.3% YoY · Filed Mar 31, 2026

HealthLynked Corp. (HLYK) files with the SEC under industry code 8011, Services-Offices & Clinics of Doctors of Medicine. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.1 million and a net loss of $3.3 million. As of Jun 30, 2026 it held $12,844 in cash and investments and $9,715 in total debt.

Revenue (TTM)
$1.37M
-46.7% vs year-ago TTM
Net income (TTM)
$-3.97M
+19.9% vs year-ago TTM
Operating cash flow (TTM)
$-1.44M
+45.4% vs year-ago TTM
Free cash flow
$-3.50M
+15.7% vs prior year
EPS (TTM)
$-1.38
-3862.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.94M
-99.0% vs prior year
Net cash
$3,129
as of Jun 30, 2026
Operating margin
-167.6%
FY 2026

Company profile

Industry
Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
Listed as
HLYK (OTC)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Naples, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1680139

Other Services-Offices & Clinics of Doctors of Medicine companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
$2.1M
$3.0M
$5.7M
$5.9M
$5.8M
Operating income
-$2.1M
-$4.7M
-$4.2M
-$8.7M
-$5.3M
Net income
-$3.3M
-$6.1M
-$1.0M
-$8.8M
-$10.4M
Diluted EPS
-$1.16
-$2.18
$0.00
-$0.04
-$0.05
Operating cash flow
-$1.7M
-$3.5M
-$4.1M
-$4.4M
-$3.8M
Free cash flow
—
-$3.5M
-$4.1M
-$4.4M
-$3.8M
Total assets
$1.7M
$2.2M
$4.3M
$4.6M
$10.7M
Total liabilities
$7.5M
$5.4M
$3.5M
$4.3M
$3.5M
Stockholders' equity
-$5.8M
-$3.1M
$804,730
$314,450
$7.2M
Cash and investments
$37,136
$76,241
$247,222
—
$3.3M
Total debt
$76,090
$362,141
$939,419
$587,794
$1.1M

Recent SEC filings

Recent SEC filings
Form Description Filed Period
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
8-K Current report
Officer or director change
Jul 16, 2026 Jul 13, 2026
10-Q Quarterly report May 15, 2026 Mar 31, 2026
10-K Annual report Mar 31, 2026 Dec 31, 2025
8-K Current report
Material agreement, New debt, Unregistered share sale
Feb 6, 2026 Feb 2, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
Dec 12, 2025 Dec 1, 2025

Source: SEC EDGAR filings. This is company-reported data, not investment advice.